Literature DB >> 18809332

Novel insights into GPCR-peptide interactions: mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensin receptor 1.

Steffen Härterich1, Susanne Koschatzky, Jürgen Einsiedel, Peter Gmeiner.   

Abstract

Investigating prototypical interactions between NT(8-13) and the human neurotensin receptor 1 (hNTR1), we created a receptor-ligand model that was validated by site-directed mutagenesis and structure-activity relationship studies. Stabilization of the extracellular loop 1 (EL1) by pi-stacking clusters proved to be important for agonist binding when substitution of six conserved amino acids by alanine resulted in an agonist specific loss of maximal binding capacity. In agreement with our modeling studies, EL1 seems to adopt a clamp-type border area controlling the shape of the binding site crevice. Employing chemically manipulated peptide analogs as molecular probes, the impact of backbone modifications on receptor-ligand interaction, especially the influence on ligand conformation, was examined in binding studies and explained by in silico analysis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18809332     DOI: 10.1016/j.bmc.2008.08.051

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  11 in total

1.  Cross-receptor interactions between dopamine D2L and neurotensin NTS1 receptors modulate binding affinities of dopaminergics.

Authors:  Susanne Koschatzky; Nuska Tschammer; Peter Gmeiner
Journal:  ACS Chem Neurosci       Date:  2011-04-11       Impact factor: 4.418

2.  Modifications at Arg and Ile Give Neurotensin(8-13) Derivatives with High Stability and Retained NTS1 Receptor Affinity.

Authors:  Lisa Schindler; Günther Bernhardt; Max Keller
Journal:  ACS Med Chem Lett       Date:  2019-05-10       Impact factor: 4.345

3.  Synthesis of a (68)ga-labeled peptoid-Peptide hybrid for imaging of neurotensin receptor expression in vivo.

Authors:  Simone Maschauer; Jürgen Einsiedel; Carsten Hocke; Harald Hübner; Torsten Kuwert; Peter Gmeiner; Olaf Prante
Journal:  ACS Med Chem Lett       Date:  2010-05-21       Impact factor: 4.345

4.  In Search of the Optimal Macrocyclization Site for Neurotensin.

Authors:  Marc Sousbie; Élie Besserer-Offroy; Rebecca L Brouillette; Jean-Michel Longpré; Richard Leduc; Philippe Sarret; Éric Marsault
Journal:  ACS Med Chem Lett       Date:  2018-01-29       Impact factor: 4.345

5.  The activity of prolactin releasing peptide correlates with its helicity.

Authors:  Stephanie H Deluca; Daniel Rathmann; Annette G Beck-Sickinger; Jens Meiler
Journal:  Biopolymers       Date:  2013-05       Impact factor: 2.505

6.  Structure of the agonist-bound neurotensin receptor.

Authors:  Jim F White; Nicholas Noinaj; Yoko Shibata; James Love; Brian Kloss; Feng Xu; Jelena Gvozdenovic-Jeremic; Priyanka Shah; Joseph Shiloach; Christopher G Tate; Reinhard Grisshammer
Journal:  Nature       Date:  2012-10-10       Impact factor: 49.962

Review 7.  Progress in structure based drug design for G protein-coupled receptors.

Authors:  Miles Congreve; Christopher J Langmead; Jonathan S Mason; Fiona H Marshall
Journal:  J Med Chem       Date:  2011-06-15       Impact factor: 7.446

8.  The E92K melanocortin 1 receptor mutant induces cAMP production and arrestin recruitment but not ERK activity indicating biased constitutive signaling.

Authors:  Tau Benned-Jensen; Jacek Mokrosinski; Mette M Rosenkilde
Journal:  PLoS One       Date:  2011-09-13       Impact factor: 3.240

9.  Modeling of the OX1R-orexin-A complex suggests two alternative binding modes.

Authors:  Lasse Karhu; Ainoleena Turku; Henri Xhaard
Journal:  BMC Struct Biol       Date:  2015-05-09

10.  In vivo monitoring of the antiangiogenic effect of neurotensin receptor-mediated radiotherapy by small-animal positron emission tomography: a pilot study.

Authors:  Simone Maschauer; Tina Ruckdeschel; Philipp Tripal; Roland Haubner; Jürgen Einsiedel; Harald Hübner; Peter Gmeiner; Torsten Kuwert; Olaf Prante
Journal:  Pharmaceuticals (Basel)       Date:  2014-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.